Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume

According to phase 2 data presented during the 2023 American Society of Hematology Annual Meeting, glofitamab monotherapy continued to demonstrate durable responses in patients with relapsed/refractory LBCL. The IRC-assessed overall and complete response (CR) rates were 52% and 40%, respectively, with the majority of CRs (65%) ongoing at data cut-off. Further, no new safety signals were observed.